Cytopathology provides diagnostic evaluation of cytology specimens that direct patient management and treatment. The Cytopathology Section provides complete diagnostic service in cytopathology for the various clinical protocols at the NIH. We specialize in the application of ancillary techniques (i.e., immunoperoxidase, flow cytometry, and, most recently, molecular testing) to patient material for the confirmation of morphologic diagnoses and collaborative investigations. The Cytopathology Section has a distribution of specimens as follows: fine needle aspiration (FNA), 26 percent;central nervous system, 31 percent;effusions, 9 percent;respiratory tract, 9 percent;genitourinary tract, 6 percent;cervical/vaginal, 7 percent;miscellaneous, 12 percent. Due to the nature of the specimen material evaluated by our Section, a large number of our cases require immunoperoxidase studies (15 percent). The immunosuppressed nature of our patient population at the NIH dictates that a significant proportion of our cases require special studies for pathologic organisms (11 percent). The relatively high rate of pathologic findings combined with the diversity of types of exfoliative and FNA specimens provide a broad experience in diagnostic cytopathology for residency and fellowship training. The Cytopathology Section is involved in numerous clinically related research studies, many of which utilize FNA or exfoliative samples with immunocytochemistry and/or molecular techniques to provide ancillary diagnostic information. A partial listing of such studies includes: (1) evaluation and quantitation of expression of malignant melanoma markers (MART-1 and gp100) and HLA antigens through the utilization of antibodies in ex-vivo FNAs from malignant melanoma patients;(2) evaluation and quantitation of expression of epithelial markers (CK AE1/AE3 and CK 8/18) and HLA antigens through the utilization of antibodies in ex-vivo FNAs from gastrointestinal carcinoma patients;(3) evaluation and quantitation of expression of epithelial markers (CK AE1/AE3 and CK 8/18) and HLA antigens through the utilization of antibodies in ex-vivo FNAs from HPV-associated carcinoma patients;(4) evaluation of tumor infiltrating lymphocytes samples for possible tumor cell contamination prior to therapy;(5) FNA material for subsequent analysis by polymerase chain reaction (PCR), microarray, and other molecular technologies;(6) evaluation of numerous cell lines by morphology and immunocytochemistry;and (7) evaluation of breast ductal lavage samples from high-risk populations for morphology and eventual biomarkers.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Scientific Cores Intramural Research (ZIC)
Project #
1ZICBC011052-06
Application #
8763755
Study Section
Project Start
Project End
Budget Start
Budget End
Support Year
6
Fiscal Year
2013
Total Cost
$1,986,045
Indirect Cost
Name
National Cancer Institute Division of Basic Sciences
Department
Type
DUNS #
City
State
Country
Zip Code
Rosenberg, Avi Z; Armani, Michael D; Fetsch, Patricia A et al. (2016) High-Throughput Microdissection for Next-Generation Sequencing. PLoS One 11:e0151775
Danforth, David N; Warner, Andrew C; Wangsa, Darawalee et al. (2015) An Improved Breast Epithelial Sampling Method for Molecular Profiling and Biomarker Analysis in Women at Risk for Breast Cancer. Breast Cancer (Auckl) 9:31-40
Wilson, Wyndham H; Bromberg, Jacoline E C; Stetler-Stevenson, Maryalice et al. (2014) Detection and outcome of occult leptomeningeal disease in diffuse large B-cell lymphoma and Burkitt lymphoma. Haematologica 99:1228-35
Layfield, Lester J; Ehya, Hormoz; Filie, Armando C et al. (2014) Utilization of ancillary studies in the cytologic diagnosis of biliary and pancreatic lesions: The Papanicolaou Society of Cytopathology Guidelines. Cytojournal 11:4
Layfield, Lester J; Ehya, Hormoz; Filie, Armando C et al. (2014) Utilization of ancillary studies in the cytologic diagnosis of biliary and pancreatic lesions: the Papanicolaou Society of Cytopathology guidelines for pancreatobiliary cytology. Diagn Cytopathol 42:351-62
Bartlett, Edmund K; Fetsch, Patricia A; Filie, Armando C et al. (2014) Human melanoma metastases demonstrate nonstochastic site-specific antigen heterogeneity that correlates with T-cell infiltration. Clin Cancer Res 20:2607-16
Erdag, Gulsun; Chowdhuri, Sinchita Roy; Fetsch, Patricia et al. (2013) Kba.62 and S100 protein expression in cytologic samples of metastatic malignant melanoma. Diagn Cytopathol 41:847-51
Murtas, D; Maric, D; De Giorgi, V et al. (2013) IRF-1 responsiveness to IFN-ýý predicts different cancer immune phenotypes. Br J Cancer 109:76-82
Sheikh, Virginia; Caplan, Margaret; Wilson, Eleanor M P et al. (2013) Cytomegalovirus immune reconstitution inflammatory syndrome manifesting as sialadenitis in an HIV-infected patient. AIDS 27:1833-5
Kemp, Clinton D; Rao, Mahadev; Xi, Sichuan et al. (2012) Polycomb repressor complex-2 is a novel target for mesothelioma therapy. Clin Cancer Res 18:77-90

Showing the most recent 10 out of 23 publications